Akèy › Leksemi mieloïd egi › Virginia › Charlottesville
Etid klinik pou Leksemi mieloïd egi nan Charlottesville, VA
16 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Charlottesville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Virginia Cancer Center, Charlottesville
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- University of Virginia Cancer Center, Charlottesville
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Virginia Cancer Center, Charlottesville
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Virginia Cancer Center, Charlottesville
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Ap rekriteFaz 3
- University of Virginia Cancer Center, Charlottesville
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Ap rekriteFaz 3
- University of Virginia Cancer Center, Charlottesville
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Ap rekriteFaz 1/2
- University of Virginia Cancer Center, Charlottesville
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- University of Virginia School of Medicine, Charlottesville
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- University of Virginia Comprehensive Cancer Center, Charlottesville
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- University of Virginia, Charlottesville
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
Ap rekriteFaz 1
- University of Virginia, Charlottesville
Cardioprotection in AML
Ap rekriteFaz 2
- University of Virginia, Charlottesville
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Ap rekriteFaz 1/2
- University of Virginia, Charlottesville
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- University of Virginia Cancer Center, Charlottesville
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Ap rekriteFaz 1/2
- University of Virginia, Charlottesville
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Ap rekriteFaz 2
- University of Virginia, Charlottesville
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- New York City, NY51 etid
- Boston, MA44 etid
- Baldwin Park, CA40 etid
- Seattle, WA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA30 etid
- Tampa, FL29 etid
- Chicago, IL26 etid
- Portland, OR25 etid
Lòt etid nan Charlottesville
- Kansè Poumon ki pa ti selil21 etid
- Kansè pwostat15 etid
- Kansè Metastatik13 etid
- Kansè Endomèt13 etid
- Kansè (tout kalite)13 etid
- Kansè poumon13 etid
- Ensifizyans kadyak11 etid
- Kansè ovè10 etid
- Kansè kolorektal10 etid
- Dyabèt tip 19 etid
- Kansè nan tete9 etid
- Kansè pankreyas9 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.